Valeant Pharma says may cut 10-15 percent jobs after Bausch & Lomb deal
(Reuters) - Canada's Valeant Pharmaceuticals International Inc (VRX.TO) (VRX.N), which has offered to buy Bausch & Lomb Holdings for $8.7 billion, said it may slash 10 to 15 percent of the combined company's workforce.
Valeant, which expects to get regulatory nod by early August, said severance plans for the United States and Canada have been finalized.
The company also said it is plans to consolidate some locations.
(Reporting by Krithika Krishnamurthy in Bangalore; Editing by Sriraj Kalluvila)
- Dallas Ebola patient vomited outside apartment on way to hospital |
- Islamic State committing 'staggering' crimes in Iraq: U.N. report
- Hong Kong police warn protesters against occupying buildings |
- Israel's Netanyahu to Obama: Don't allow Iran deal that leaves it at nuclear threshold
- Islamic State presses assault on Syrian border town, Kurds warn Turkey |